Diflomotecan (Synonyms: BN 80915)

Cat. No.: HY-13611: FAQs
Data Sheet Handling Instructions

Molarity Calculator

Diflomotecan (BN 80915) is a potent and orally active inhibitor of topoisomerase I. Diflomotecan (BN 80915) causes enhanced plasma stability and has the superior preclinical anti-tumour activity compared with other established compounds.

For research use only. We do not sell to patients.

Diflomotecan Chemical Structure

CAS No. : 220997-97-7

Size		Stock
MOQ		Minimum order quantity
50 mg		Get quote
100 mg		Get quote
250 mg		Get quote
Other size		Get quote

Synthetic products have potential research and development risk.

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Featured Recommendations

•Related Small Molecules:

•Related Proteins:

View All Topoisomerase Isoform Specific Products:

View All Isoforms

Topoisomerase Topo I Topo II

Biological Activity
Purity & Documentation
References
Customer Review

Description

IC₅₀ & Target

topoisomerase I^[1]

Cellular Effect

Cell Line	Type	Value	Description	References
A549	IC₅₀	3.4 nM Compound: 12	Cytotoxicity against human A549 cells by WST assay Cytotoxicity against human A549 cells by WST assay	[PMID: 23578545]
A549	IC₅₀	3.4 nM Compound: 8f	Cytotoxicity against A549 tumor cell line determined by WST-1 assay Cytotoxicity against A549 tumor cell line determined by WST-1 assay	[PMID: 10841808]
HT-29	IC₅₀	8.4 nM Compound: 8f	Cytotoxicity against HT-29 tumor cell line determined by WST-1 assay Cytotoxicity against HT-29 tumor cell line determined by WST-1 assay	[PMID: 10841808]
T-24	IC₅₀	0.4 nM Compound: 12	Cytotoxicity against human chemo-resistant T24 cells by WST assay Cytotoxicity against human chemo-resistant T24 cells by WST assay	[PMID: 23578545]
T-24	IC₅₀	0.4 nM Compound: 8f	Cytotoxicity against T24 tumor cell line determined by WST-1 assay Cytotoxicity against T24 tumor cell line determined by WST-1 assay	[PMID: 10841808]

Clinical Trial

Molecular Weight

398.36

Formula

C₂₁H₁₆F₂N₂O₄

CAS No.

220997-97-7

SMILES

O=C(OC1)C[C@](O)(CC)C2=C1C(N3CC4=CC5=CC(F)=C(F)C=C5N=C4C3=C2)=O

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Please store the product under the recommended conditions in the Certificate of Analysis.

Purity & Documentation

Handling Instructions (2659 KB)

References

[1]. Kroep JR, et al. Diflomotecan, a promising homocamptothecin for cancer therapy. Expert Opin Investig Drugs. 2009;18(1):69-75. [Content Brief]

[2]. Gelderblom H, et al. Phase I pharmacological and bioavailability study of oral diflomotecan (BN80915), a novel E-ring-modified camptothecin analogue in adults with solid tumors. Clin Cancer Res. 2003;9(11):4101-4107. [Content Brief]

Diflomotecan Related Classifications

Molarity Calculator
Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass		Concentration		Volume		Molecular Weight *
	=		×		×

The dilution calculator equation

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Concentration _(start)	×	Volume _(start)	=	Concentration _(final)	×	Volume _(final)
	×		=		×
C1		V1		C2		V2

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Diflomotecan220997-97-7BN 80915BN80915BN-80915Topoisomeraseoraltopoisomerase Iplasma stabilityanti-tumourpreclinicalInhibitorinhibitorinhibit

Your Recently Viewed Products:

Product Name

Salutation

Applicant Name *

Email Address *

Phone Number *

Organization Name *

Department *

Requested quantity *

Country or Region *

Remarks